UnknownPhase 4

Taurolock Hep 500 Versus Unfractionated Heparin as Anti-inflammatory in Hemodialysis Catheters.

Egypt60 participantsStarted 2018-05-15

Plain-language summary

To assess the efficacy of Taurolock-hep500™ as anticoagulant and antimicrobial catheter lock solution in comparison to unfractionated heparin as alock solution to improve performance of hemodialysis catheters and quality of hemodialysis .

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients on regular hemodialysis 3sessions/wk.
✓. Recent catheter insertion at beginning of the study.
✓. Both males and females.
✓. Age group ≥ 18 ys.

Exclusion criteria

✕. Patients with intercurrent infections.
✕. Patients with sepsis.
✕. Patients receiving drugs affecting immune system like immunosuppressive drugs.
✕. Patients on antibiotics.

What they're measuring

Prevention of inflammation in hemodialysis patients through hemodialysis catheters

Timeframe: one month

Trial details

NCT IDNCT03539718

SponsorAin Shams University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-11

Contact for this trial

Magdy Sharkawy, MD

002010-014-22331 Magdi35@hotmail.com

View on ClinicalTrials.gov More Hemodialysis Catheter Infection trials